- Sequenom - Es gibt News. - 500 Beiträge pro Seite

[MatzeKlug]

Was meint Ihr. Gibt´s Auswirkungen auf den Kurs?

SEQUENOM Completes the Largest SNP Assay Design and Validation Project to Date Unprecedented Study with the National Cancer Institute Leads to Additional Agreement
TUESDAY, AUGUST 08, 2000 6:30 AM
- PRNewswire

SAN DIEGO, Aug 8, 2000 /PRNewswire via COMTEX/ -- SEQUENOM, Inc. (Nasdaq:SQNM) today announced that it has successfully completed the largest SNP assay design and validation project to date in collaboration with the National Cancer Institute (NCI), the federal government`s principal agency for cancer research and training. As the first phase of the jointly funded collaboration, SEQUENOM`s automated assay design process and proprietary MassARRAY(TM) system were used to develop more than 9000 assays to confirm and validate single nucleotide polymorphisms (SNPs) in a reference population. As a result of the successful completion of this project, the NCI has contracted with SEQUENOM for a second process phase with the goal to develop an additional set of 10,000 SNP assays for confirmation and validation.

"This study positions SEQUENOM as the leader in industrial genotyping," said Toni Schuh, Ph.D., SEQUENOM`s President and CEO. "The completion of the first phase of this project with the NCI demonstrates our ability to rapidly develop, and efficiently and accurately execute large-scale gene-based association studies. We believe that the confirmed SNP assay portfolio generated from this study represents the largest in the world. The successful development of this assay portfolio provides SEQUENOM with the basis to routinely deploy high throughput analysis of these SNPs, providing high quality, valuable data and important genetic information along with our MassARRAY subscriptions. These assays will be important value-added products for the Company."

Andi Braun, M.D., Ph.D., SEQUENOM`s Chief Medical Officer and head of the Company`s Genomics Business, added, "There are a number of significant factors that we have combined to make this type of study possible. The unique combination of the speed and efficiency of our assay development process, the cost effectiveness of using unmodified and unpurified reagents and the precision of the analytical technology, coupled with our ability to analyze hundreds of samples in a single reaction, gives SEQUENOM a major competitive advantage in generating high quality genotyping data. The Company`s extensive databases and powerful bioinformatics tools provide the capacity to leverage SNP data to uncover the relationships between individual DNA variations and disease, with widespread applications in drug discovery and development as well as diagnostics and personalized medicine."

According to Kenneth Buetow, Ph.D., Chief, Laboratory of Population Genetics and a member of NCI`s Genetic Annotation Initiative, the results of this study will be placed in the public domain on a NCI web site. However, given the study`s significance, information regarding the specific results and procedures have been reserved and submitted for publication in a major scientific journal.

SEQUENOM has recently developed an automated, computer assisted assay design process. While some genotyping systems, including MassARRAY, have the capacity to analyze tens of thousands of SNPs a day, assay design is consistently the bottleneck before the analyses can take place. SEQUENOM`s automated process is capable of developing thousands of assays a day by negating the need for time-consuming optimization of assay conditions, thereby streamlining sample processing. Following initial assay design, the fidelity of each SNP assay is confirmed using a reference DNA pool and the Company`s MassARRAY system, which measures the DNA samples directly and with an unprecedented level of accuracy. By screening the confirmed SNPs against disease populations and SEQUENOM`s healthy population-based DNA bank, the Company can identify the major genetic contributors to human complex disorders, such as cardiovascular disease or cancer.

SEQUENOM is a post-genomics company translating information generated from the map of the human genome into practical applications by offering a comprehensive genotyping technology to determine the medical relevance of genetic variations. SEQUENOM`s distinct competitive advantage is a bottleneck-free SNP analysis solution consisting of its highly accurate and robust MassARRAY system, an automated assay development process and assay database, the ability to analyze hundreds of samples in a single reaction and a proven health-based concept for genetic marker validation. As a leader in SNP analysis, SEQUENOM offers its powerful technology to customers in diagnostics, pharmacogenomics, drug development and agricultural biotechnology, while using the MassARRAY technology with a novel scientific strategy for in-house programs to identify the medical utility of SNPs. SEQUENOM is headquartered in San Diego, California with offices in Hamburg, Germany and Boston, Massachusetts.

All statements in this press release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for SEQUENOM from those projected. Those factors include risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of SEQUENOM products, dependence on collaborative partners, such as NCI, successful performance under NCI and other collaborative agreements, competition, the intellectual property of others, patent protection and other risk factors discussed from time to time in SEQUENOM`s reports and filings with the Securities and Exchange Commission, including SEQUENOM`s Annual Report on Form 10-K for the year ended December 31, 1999 and most recent Quarterly Report on Form 10-Q. SEQUENOM expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in SEQUENOM`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

SOURCE SEQUENOM, Inc.

CONTACT: Abigail Devine, APR, Investor Relations of SEQUENOM, Inc.,
858-350-0345, [e-mail]; or Media: Ana Kapor of Noonan/Russo
Communications, 415-677-4455, ext. 207, [e-mail]

[gimmequote!]

hi,

blies, mach ma in deutsch!

danke

gimmequote!